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Protein kinase C (PKC) is a family of kinases that are implicated in a plethora of diseases, including cancer and cardiovascular
disease. PKC isoforms can have diﬀerent, and sometimes opposing, eﬀects in these disease states. Toll-like receptors (TLRs) are a
family of pattern recognition receptors that bind pathogens and stimulate the secretion of cytokines. It has long been known that
PKC inhibitors reduce LPS-stimulated cytokine secretion by macrophages, linking PKC activation to TLR signaling. Recent studies
have shown that PKC-α,- δ,- ε, and -ζ are directly involved in multiple steps in TLR pathways. They associate with the TLR or
proximal components of the receptor complex. These isoforms are also involved in the downstream activation of MAPK, RhoA,
TAK1, and NF-κB. Thus, PKC activation is intimately involved in TLR signaling and the innate immune response.
1.Introduction
Protein kinase C (PKC) is a family of protein serine
/threonine kinases centrally involved in intracellular signal
transduction. The PKC isoforms are divided into 3 subfami-
lies based on their activation requirements: the conventional
isoforms, PKC-α,- βI, -βII, and -γ, require calcium, diacyl-
glycerol, and phosphatidylserine; the novel isoforms, PKC-δ,
-ε,- η,a n d– θ, require diacylglycerol and phosphatidylserine
but are calcium independent; the atypical isoforms, PKC-
ζ and λ/ι, require only phosphatidylserine [1]. Diﬀerent
isoforms of PKC are involved in such pivotal functions as cell
growth, diﬀerentiation, apoptosis, motility, and secretion.
Accordingly, these enzymes have been implicated in many
disease states including cancer and cardiovascular disease
[2–6]. The role of PKC in cancer is complicated by the
tissue-speciﬁc, and often opposing, eﬀects of the diﬀerent
isoforms on cell cycle and apoptosis. Similarly, the role of
PKC in heart disease is complex because components of
the disease (myocyte hypertrophy, cardiac function, ﬁbrosis,
and inﬂammation) are inﬂuenced in diﬀerent ways by the
diﬀerent isoforms.
Toll-like receptors (TLRs) are a family of pattern recog-
nition receptors that are critical for the eﬀective innate
immuneresponsetoinfection[7–9].Signalingfromdiﬀerent
TLRs varies but is initiated by the recruitment of TIR-
containing adaptor proteins (e.g., TIRAP recruits MyD88,
TRAM recruits TRIF). MyD88 recruits IRAK4, IRAK1,
IRAK2, and TRAF6. Phosphorylation and degradation of
IRAK1 releases this complex into the cytoplasm where it
binds and activates TAK1 downstream. Through an as yet
unknown, and possibly indirect, mechanism, TAK1 activates
the IKKβ → IkB-α → NF-κB pathway for induction
of proinﬂammatory genes. TAK1 also activates the MAPK
cascadesthatinﬂuencegeneexpression.TLRbindingofTRIF
recruits TRAF6, βRIP1, and TAK1 for activation of MAPK,
IRF3, NF-κB, and transcription of interferon-β.T h eT R I F
pathway also stimulates the secretion of proinﬂammatory
cytokines although to a lesser degree than the MyD88
pathway.
Initial evidence for the involvement of PKC in TLR sig-
naling came from observations that altering PKC activity
in cells of the innate immune system aﬀected cytokine
secretion. Subsequently, LPS and other TLR ligands were
shown to activate most of the PKC isoforms expressed in
monocytes, macrophages, dendritic cells, and neutrophils
[10–14]. A large number of studies have shown that phar-
macological inhibition of PKC, or its depletion by long-term
treatment with phorbol esters, decreases LPS-stimulated2 Enzyme Research
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Figure 1: PKC isoforms act at many levels in TLR signaling. PKC-α
associates with the TLR2 signaling complex in a MyD88-dependent
manner. PKC-α is also required for TLR3-mediated IRF-3 binding
to CBP and IFN-β gene induction. Interaction of PKC-δ with
TIRAP is required for the downstream activation of NF-κB. PKC-
ε associates with complexes of MyD88 and TLR2 or TLR4 and is
necessary for downstream signaling. PKC-ε is also required for the
phosphorylation of TRAM. PKC-ζ is activated upon ligation of
TLR2 or TLR4. During signaling by these receptors, active PKC-ζ
binds to TLR2, associates with TRAF6 and RhoA, and is required
for full transcriptional activation of p65.
cytokine secretion [10, 15–17]. Accordingly, acute activation
of PKC with phorbol esters increases cytokine secretion
[11, 15, 17, 18].
Results from studies performed over the last decade have
identiﬁed four PKC isoforms that impact diﬀerent steps in
TLR signaling. This paper will summarize recent advances
detailing the role of PKC-α,- δ,- ε,a n d- ζ in activation of the
initial TLR signaling complex, activation of RhoA, and tran-
scription factors (Figure 1).
2. PKC Isoforms Involved in TLR Signaling and
Host Defense
2.1. PKC-α. Conventional PKC isoforms have been impli-
cated in cytokine secretion by several studies showing
that G¨ o6976, which inhibits PKC-α and β, blocks TLR-
stimulated cytokine secretion by macrophages [14, 19–
22]. A series of studies found that 264.7 RAW macro-
phages expressing a dominant negative (DN) PKC-α have
reduced LPS-stimulated TNF-α,I L - 1 β, iNOS, and NF-IL6
(CAAT/enhancer-binding protein β) induction [23, 24].
These cells also had defects in phagocytosis, phagosome
maturation,andkillingofintracellularpathogens,suggesting
that PKC-α is also involved in other, non-TLR-mediated
aspects of innate immunity [25–28]. A further link between
PKC-α and TLR-mediated responses is the ﬁnding that
PPARγ modulates phorbol ester-induced NF-κBa c t i v a t i o n
and TNF-α secretion by preventing the activation of PKC-α
[18].
Findings by Langlet et al. [29] revealed that, in human
DC, PKC-α inhibition blocked IL-12p40 secretion induced
by TLR2/6, TLR 2/1, TLR5, and IL-1R, but not TLR3. The
role of PKC-α was dissected using G¨ o6976, expression of
DN PKC-α, and DC from PKC-α−/− mice. Using these ap-
proaches, it was determined that activation of PKC-α is
required for TLR2/1-mediated activation of MAPK, NF-κB,
a n dA P - 1a sw e l la ss e c r e t i o no fT N F - α, IL-6, and IL-10
by DC. That immunoprecipitation of PKC-α from TLR2/1-
activated DC captured TLR2 provides additional evidence
that PKC-α is linked to TLR2 signaling. As TLR2 was not
foundinPKC-αimmunoprecipitatesofcellsfromMyD88−/−
mice suggests that MyD88 links TLR2 with PKC-α.
Johnson et al. [30] found that poly (I:C), a TLR3 ligand,
activated PKC-α. Downregulation of PKC-α with siRNA, or
expression of DN PKC-α, blocked TLR3-stimulated IFN-β
production in dendritic cells (DCs). Interfering with PKC-
α activity did not change the activation of IRF3 in terms
of phosphorylation, dimerization, nuclear translocation, or
DNA binding but did inhibit IRF-3 transcriptional activity
induced by TRIF and TBK1 overexpression. This latter eﬀect
is due to decreased IRF-3 binding to the coactivator, CREB
binding protein (CBP) which requires PKC-α activation.
2.2. PKC-δ. Several studies have implicated PKC-δ in TLR-
mediated cytokine secretion [12, 31–34]. Inhibition of
PKC-δ with Rottlerin, or its downregulation, consistently
decreases activation of NF-κB, secretion of inﬂammatory
cytokines, and production of nitric oxide by cells of the
innate immune system. Results from Kubo-Murai et al. [35]
suggest that PKC-δ is involved in TLR signaling through its
interaction with TIRAP. Speciﬁcally, PKC-δ in macrophage
lysates bound to immobilized TIRAP via the TIR domain of
TIRAP. Additionally, PKC-δ depletion results in the loss of
kinase activity in immobilized TIRAP implicating PKC-δ as
therelevantkinaseforpropagatingsignalingfromtheTIRAP
complex. That downregulation of PKC-δ severely depresses
the activation of p38 MAPK and NF-κB by ligands for TLR4,
and TLR2 underscores its importance in signaling via these
receptors. To date, this is the only report demonstrating a
direct role for PKC-δ in TLR signaling.
Cecal ligation and puncture (CLP) is an established
animal model for sepsis and has been used to study TLR
signaling in vivo. Recently, it was shown that, when admin-
istered intratracheally, a PKC-δ-inhibiting peptide reduced
the lung injury associated with CLP-induced sepsis in rats
[36]. This inhibitor blocked sepsis-induced phosphorylation
of PKC-δ. Animals given the inhibitor prior to CLP had
reduced levels of the chemokines CINC-1 and MIP-2 in
lung lavage and blood samples. At the same time, there was
reduced inﬁltration of inﬂammatory cells into the lungs and
less pulmonary edema. The authors linked the protective
eﬀects of the inhibitor to reduced NF-κB activation and
chemokine production by macrophages, endothelial cells,
andepithelialcells[37–39].Thisisconsistentwithaprevious
study showing that PKC-δ−/− mice had reduced cytokine
production, neutrophil inﬁltration, and lung injury due to
asbestos [40].Enzyme Research 3
Sphingosine kinase 1 (SphK1) has been implicated in in-
ﬂammation through the formation of sphingosine 1 phos-
phate[41–44].SphK1isinducedandactivatedbyseveralim-
mune stimuli including LPS. In LPS-treated macrophages,
PKC-δ lies downstream of SphK1 activation and is required
for the activation of NF-κB[ 37]. Furthermore, the inhibi-
tion of SphK1 in vivo reduced LPS- and sepsis-stimulated
cytokine secretion and mortality. These studies support
a TLR4→SphK1→PKC-δ →NF-κB→cytokine pathway. It
remains to be determined if the same pathway links SphK1
to TNFR1 and IL-1R [43, 44].
Beyond the scope of this paper are the eﬀects of this PKC
isoforminseveralTLR-independentaspectsofinﬂammation
including signaling via TNFR1, neutrophil activation, and
endothelial cell function [43–48].
2.3. PKC-ε. Ar o l ef o rP K C - ε in host defense was apparent
when Castrillo et al. [49] observed that PKC-ε−/− mice were
diﬃculttobreedduetoinfectionsoftheuterus.Additionally,
these animals had a 2- to 3-fold reduction in survival
time after infection with Gram-negative or Gram-positive
bacteria. Several aspects of the immune system in these
animals were normal although macrophages were defective
in the production of LPS-stimulated TNF-α,I L - 1 β,P G E 2,
and nitric oxide. There were also deﬁcits in LPS-stimulated
MAPK and NF-κB activation. Other studies, using PKC-ε-
speciﬁcinhibitors,depletionwithantisenseoligonucleotides,
and macrophages from PKC-ε−/− mice, veriﬁed that PKC-ε
is critical for LPS-stimulated TNF-α and IL-12 secretion by
DC and macrophages [10, 50, 51]. In vivo administration of
aP K C - ε inhibitor reduced the inﬂammation associated with
amurinemodelofcardiactransplantation[52].Thus,PKC-ε
has a likely role in inﬂammation and host defense [53, 54].
More recent studies have sought to clarify the role of
PKC-εinTLRsignaling.PKC-εisphosphorylatedbyallTLRs
that signal through MyD88, that is, TLR1 through 9 except
TLR3 in macrophages [55]. Upon TLR4 ligation with LPS,
PKC-ε is phosphorylated on Ser-346 and 368 and binds to
14-3-3β. Association with 14-3-3β requires the presence of
MyD88. Phosphorylation of these serines is critical for PKC-
ε signaling as cells expressing PKC-ε S346A/S368A fail to
activate an NK-κB reporter in response to ligands for TLR4
and TLR2. These ﬁndings suggest that the complex of TLR,
MyD88, 14-3-3β, and PKC-ε is required for gene induction.
Of note, since PKC-ε can be phosphorylated by PKC-α,i ti s
possible that the eﬀects of PKC-α on cytokine secretion are
shared by PKC-ε [56, 57].
In addition to its role in MyD88-dependent signaling,
PKC-ε is also involved in TLR4 activation via the TRAM
pathway. The TRAM pathway primarily stimulates the pro-
duction of IFN-β and RANTES. Phosphorylation of TRAM
in LPS-stimulated macrophages allows it to dissociate from
the membrane and bridge TLR4 with TRIF. McGettrick et al.
[11] found that recombinant PKC-ε,b u tn o tP K C - ζ, phos-
phorylates TRAM on Ser-16, and TRAM−/− macrophages
reconstituted with TRAM S16A do not signal. That this
phosphorylation of TRAM did not occur in PKC-ε−/− cells
and that macrophages from PKC-ε−/− mice have reduced
production of IFN-β places PKC-ε in the TLR4→ PKC-ε →
Ser-16 TRAM→ IFN-β pathway.
2.4. PKC-ζ. This atypical PKC isoform is a component
of the signaling pathways for IL-1R and TNFR [58–60].
More recently, PKC-ζ has been shown to be involved in the
activation of TLR, IRAK, RhoA, and NF-κB[ 61–64].
PKC-ζ is downstream of TLR2 in human macrophages
stimulated with Mycobacterium tuberculosis (MTB) [64].
Speciﬁc inhibitors of PKC-ζ or its downregulation blocked
ERK activation and TNF-α secretion stimulated by MTB.
PKC-ζ was also found to associate with immunoprecipitated
TLR2 but not TLR4 after stimulation with MTB or pep-
tidoglycan. Finally, PKC-ζ did not associate with TLR2 in
THP-1 cells expressing DN PKC-ζ. These results suggest a
TLR2 → PKC-ζ → ERK pathway for production of TNF-α
in response to MTB.
IRAKphosphorylation is anearly event in TLR signaling.
Phosphorylated IRAK is subsequently degraded which acts
as a negative feedback control on the signaling pathway.
Using a panel of protein kinase inhibitors, Hu et al. [61]
demonstrated that the phosphorylation of IRAK by TLR4
is mediated by PKC in THP-1 cells. PKC-ζ was found
in IRAK immunoprecipitates from LPS-stimulated cells.
Furthermore, macrophages from wild-type mice responded
to LPS with activation of PKC-ζ and phosphorylation of
IRAK, but macrophages from C3H/HeJ mice that have a
nonfunctional TLR4 did not. Although not yet directly
tested, these results suggest that IRAK is a PKC-ζ substrate.
Several studies have highlighted a role for RhoA in TLR
signaling [65–69]. Two papers have directly implicated PKC-
ζ in TLR2 and TLR4 signaling through the activation of
RhoA and subsequent activation of NF-κB[ 62, 63]. Teusch
et al. [63] found that full transcriptional activation of p65
by TLR2 ligands in monocytic cells requires the activity of
both RhoA and PKC-ζ. Inhibition of PKC-ζ, or expression of
its dominant negative mutant, reduces the phosphorylation
of p65 on serine 311 and its transcriptional activity. PKC-ζ
transiently associates with RhoA with a time course similar
to that of RhoA activation. The authors concluded that PKC-
ζ mediates at least part of the eﬀects of RhoA on gene
transcription.
Further reﬁnement of the position of PKC-ζ in the
TLR→RhoA → NF-κB pathway has been elucidated by the
studies of Huang et al. [62]. They reported that treatment of
m a c r o p h a g e sw i t hL P Sa c t i v a t e sP K C - ζ and that interfering
with PKC-ζ activation blocks LPS-stimulated activation of
NF-κB and cytokine production. As in the TLR2 studies
above, PKC-ζ was present in anti-RhoA or anti-TRAF6
immunoprecipitates of cell lysates from LPS-stimulated
macrophages. Inhibition of RhoA or TRAF6 blocked PKC-ζ
activation, placing PKC-ζ downstream of RhoA and TRAF6.
Similar experiments place TAK1 between PKC-ζ and NF-κB.
That is, inhibition of PKC-ζ blocked TAK1 phosphorylation,
and constitutively active PKC-ζ f a i l st oa c t i v a t eN F - κBi n
TAK1-depleted cells. Together, these studies are consistent
with the following model: TLR2/4→ RhoA/TRAF6→ PKC-
ζ → TAK1 → s311 p65 → cytokine induction.4 Enzyme Research
Cigarette smoke is a major cause of lung inﬂammation
which is exacerbated by its common contamination with
LPS. Yao et al. [70] recently demonstrated that PKC-ζ−/−
mice exposed to smoke/LPS had less lung inﬂammation than
wild-type mice. Bronchoalveolar cells from mice exposed
to smoke/LPS had activated PKC-ζ that translocated to the
nucleus in association with p65 and CBP. This was associated
with the phosphorylation (Ser311) of p65 and induction of
cytokines.AlloftheseeventswerereducedinPKC-ζ−/− mice.
Surfactant protein A (SP-A) limits several aspects of in-
ﬂammation in the lung, partly due to stabilization of IkB-
α [71]. Moulakakis et al. [72] found that PKC-ζ is required
for this eﬀect. SP-A activates PKC-ζ, limits its translocation
to the nucleus, and stabilizes IkB-α.I na l v e o l a rm a c r o p h a g e s
from PKC-ζ−/− mice, these protective eﬀects were lost. That
is, in PKC-ζ−/− macrophages, SP-A failed to inhibit LPS-
stimulated IkB-α activation, and NF-κB DNA binding was
nearly normal. It was concluded that the eﬀect of SP-A →
PKC-ζ axis may function as a brake on the inﬂammatory
response of alveolar macrophages.
3.Perspective
The establishment of PKC in TLR signaling as well as
in other inﬂammatory processes may provide a means
to treat inﬂammatory diseases. Inhibition of a kinase
required for so many important biological functions may be
expected to result in substantial side eﬀects. However, several
inhibitors of PKC have proven to be well tolerated in clinical
trials [73–75].
The studies detailed above provide convincing evidence
that PKC is directly involved in TLR signaling. In most
cases, further studies are needed to determine the nature of
the interaction between PKC isoforms and other proteins
in the signaling cascades and then to identify the speciﬁc
PKC substrates. Another important area of investigation is
the integration of the TLR→PKC axis with the involvement
of these same isoforms (PKC-α,- δ,a n d- ζ) and possible
interaction of the isoforms in non-TLR-dependent aspects of
innateimmunity.PKC-αmaycontributetophagocytosisand
pathogen killing [25–28], PKC-δ is involved in signaling via
TNFR1, neutrophil activation, and endothelial cell function
[43–48], and PKC-ζ participates in signaling through TNFR
and IL-1R [58–60]. Thus, PKC isoforms likely sit at diﬀerent
nodesinthesignalingweb.Understandingtheircontribution
to individual pathways as well as their position in the web
is necessary to avoid misinterpreting results of experiments
such as one in which a PKC inhibitor appears to reduce the
TNF-α response to a TLR ligand, but, in fact, the inhibitor
blocked the secondary augmentation of TNF-α secretion
mediated through the TNFR. Finally, understanding the role
of TLR-mediated activation of speciﬁc PKC isoforms will
immediately provide insights into the mechanisms of the
disease.
One of the more important advances during the 20th
century was the alleviation of a great deal of the suﬀering
from infectious diseases. We may hope for a similar advance
with regard to inﬂammatory diseases in the 21st century.
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